Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
130 results about "Immune modulator" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
An immune modulator is a substance that modulates and balances the activity of the immune system.
Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
InactiveUS20080085870A1Reduce in quantityDecreased immunological responseOrganic active ingredientsPeptide/protein ingredientsAntigenAdjuvant
The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized HCMV antigen as described above, and further comprising adjuvants, excipients, or immune modulators.
Owner:VICAL INC
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
ActiveUS8481029B2Promotes strong expression of 4-1BBImprove responseAntibacterial agentsNervous disorderAutoimmune responsesImmune modulator
Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-IBB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.
Owner:UNIV OF SOUTHAMPTON
B7S1: an immune modulator
InactiveUS20050163772A1Inhibition of activationInhibits T cell activationCompound screeningApoptosis detectionImmune modulatorAntibody
The invention provides B7S1 nucleic acid, B7S1 polypeptides, and antibodies that bind B7S1 polypeptides. B7S1 sequences can be used, e.g., to screen for modulators of B7S1 activity. Modulators, e.g., antibodies or small molecules, can be used for the treatment of disease that involve an immune response.
Owner:UNIV OF WASHINGTON
Cancer therapy via a combination of epigenetic modulation and immune modulation
ActiveUS20160193239A1Improve immunityAnti-neoplastic effect of the immune modulating agent in the subject is enhancedOrganic active ingredientsMicrobiological testing/measurementAntiendomysial antibodiesImmune modulator
Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Human immune therapies using a cd27 agonist alone or in combination with other immune modulators
InactiveUS20130336976A1Promotes strong expression of 4-1BBImprove responseAntibacterial agentsAntimycoticsIMMUNE STIMULANTSCD8
Methods of inducing T cell proliferation and expansion in vivo for treating conditions wherein antigen-specific T cell immune response are therapeutically desirable such as cancer, infection, inflammation, allergy and autoimmunity and for enhancing the efficacy of vaccines are provided. These methods comprise the administration of at least one CD27 agonist, preferably an agonistic CD27 antibody, alone or in association with another moiety such as immune stimulant or immune modulator such as an anti-CD40, OX-40, 4-1BB, or CTLA-4 antibody or an agent that depletes regulatory cells, or a cytokine. These mono and combination therapies may also optionally include the administration of a desired antigen such as a tumor antigen, an allergen, an autoantigen, or an antigen specific to an infectious agent or pathogen against which a T cell response (often CD8+) is desirably elicited.
Owner:UNIV OF SOUTHAMPTON
Antineoplastic combinations of temsirolimus and sunitinib malate
A combination of temsirolimus and sunitinib malate in the treatment of cancer is provided. Also provided are regimens and kits for treatment of renal cell carcinoma, containing temsirolium and sunitinib malate, optionally in combination with other anti-neoplastic or immune modulators.
Owner:WYETH
Codon-optimized polynucleotide-based vaccines against Bacillus anthracis infection
The invention is related to polynucleotide-based anthrax vaccines. In particular, the invention is plasmids operably encoding Bacillus anthracis antigens, in which the naturally-occurring coding regions for the B. anthracis antigens have been modified for improved translation in human or other mammalian cells through codon optimization. In certain embodiments, the coding regions are also modified so as to remove potential N-linked glycosylation sites. B. anthracis antigens which are useful in the invention include, but are not limited to protective antigen (PA), lethal factor (LF), and fragments, variants or derivatives of either of these antigens. The invention is further directed to methods to induce an immune response to B. anthracis in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized B. anthracis antigen as described above. The invention is also directed to pharmaceutical compositions comprising plasmids encoding a codon-optimized B. anthracis antigen as described above, and further comprising adjuvants, excipients, or immune modulators.
Owner:VICAL INC
Methods of Enhanced Detection and Therapy of Inflamed Tissues Using Immune Modulation
InactiveUS20080193376A1Increase choiceIncrease the uptake of diagnosticPhotodynamic therapyRadioactive preparation carriersVulnerable plaqueImmune Modulators
The present invention relates to methods for the detection and therapy of active atheromatous plaques, and in particular vulnerable plaques, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by the inflammatory cells associated with such plaques.
Owner:THE GENERAL HOSPITAL CORP
Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
Disclosed herein is a composition and a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and / or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin, and defensins were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.
Owner:HOUSE EAR INSTITUTE
TGF-β1 specific antibodies and methods and uses thereof
ActiveUS9518112B2Less responseLess toxicityImmunoglobulins against growth factorsAntibody ingredientsDiseaseAnticarcinogen
Owner:LUDWIG INST FOR CANCER RES LTD
Vaccine
InactiveUS20060013830A1Less susceptibleMinimal toxicityBiocideBacterial antigen ingredientsImmune modulatorTsukamurella
The invention relates to a method for treating or preventing (including immunising against) post-weaning multisystemic wasting syndrome (PMWS) and / or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the genera Rhodococcus, Gordonia, Nocardia, Dietzia, Tsukamurella and Nocardioides, in the manufacture of a medicament for the treatment or prevention of post-weaning multisystemic wasting syndrome (PMWS) and / or porcine dermatitis and nephropathy syndrome (PDNS).
Owner:UCL BUSINESS PLC
Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
InactiveUS20130209463A1Less frequent dosingReduce riskBiocideSenses disorderImmune modulatorAutoimmune disease
This invention relates to a protein C1ORF32 and its variants and fragments and fusion proteins thereof, and methods of use thereof for immunotherapy, and drug development, including but not limited to as immune modulators and for immune therapy, including for autoimmune disorders.
Owner:COMPUGEN
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
ActiveUS20110033449A1Profound effect on anti-tumor immunityImprove scalabilityAntibacterial agentsAntimycoticsAutoimmune responsesImmune modulator
Owner:UNIV OF SOUTHAMPTON
Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
InactiveUS20060188439A1Reduce and prevent inactivationEasy to manufactureHybrid immunoglobulinsIn-vivo radioactive preparationsAnticarcinogenImmune modulator
The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and / or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer for which the contemplated antibody is effective in treating also include leukemia and lymphoma. In a preferred imbodiment the recombinant antibodies of the current invention were produced in and purified from the milk of transgenic animals. In another preferred embodiment of the current invention the agonistic anti-CD137 antibodies of the invention can be conjugated to radionuclides for radioimmunodetection or radioimmunotherapeutic purposes, or conjugated to a toxin for enhanced therapeutic treatment of various cancers.
Owner:GTC BIOTHERAPEUTICS INC
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
ActiveUS20170157048A1Antibacterial agentsGenetic material ingredientsSpherical nucleic acidImmune Modulators
Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
Owner:EXICURE INC
Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
InactiveUS20080019905A9Reduce and prevent inactivationEasy to manufactureHybrid immunoglobulinsIn-vivo radioactive preparationsAnticarcinogenImmune modulator
Owner:GTC BIOTHERAPEUTICS INC
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
Owner:SYNLOGIC OPERATING CO INC
Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
InactiveUS20130280167A1Reduce and block cell deathStabilize neuronNervous disorderSugar derivativesImmune modulatorDisease specific
Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful for neuroprotection and in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and / or with other antibodies or fragments thereof. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.
Owner:MAYO FOUND FOR MEDICAL EDUCATION & RES
Methods and compositions for treating cancer and infectious diseases
ActiveUS20170007698A1Prevention and reduction of severityShorten the progressOrganic active ingredientsAntibody ingredientsInfectious DisorderImmune modulator
The invention relates to compositions comprising a CD4 lymphocyte depleting agent; and methods of using the compositions to treat, prevent, reduce the severity of and / or slow the progression of a condition in a subject. The invention also relates to use of combinations of a CD4 lymphocyte depleting agent and at least one additional agent to treat, prevent, reduce the severity of and / or slow the progression of a condition in a subject. The additional agent may be an immune check point inhibitor, an adoptive immune therapeutic, an immune adjuvant, or an immune modulating agent, or their combinations.
Owner:CEDARS SINAI MEDICAL CENT
Herbal nutraceuticals and a process for preparing the same
The present invention relates to a novel herbal nutraceutical and more particularly to novel herbal jams and jellies with proven pharmacological activities such as memory enhancer, antioxidant, anti-depressant, immuno-modulator, adapatogen, health promoter and chemically standardized on the basis of one or more bioactive constituents and also to a process for the manufacture of said herbal nutraceuticals.
Owner:COUNCIL OF SCI & IND RES
Methods and compositions for treating allergy and inflammatory diseases
InactiveUS20170095573A1Decreasing Th2-typeIn-vivo radioactive preparationsAntipyreticAntigenTlr agonists
Described herein are therapeutic approaches with immune modifiers of the Th2 pathway for the treatment of allergic and inflammatory diseases. Aspects of the disclosure relate to methods for decreasing Th2-type cell responses in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an anti-Dectin-1 antibody or antigen binding fragment thereof operatively linked to a TLR agonist.
Owner:BAYLOR RES INST
Methods and compositions related to plunc polypeptides
InactiveUS20050192221A1Inhibit microbial growthPrevent proliferationAntibacterial agentsBiocideImmunomodulating AgentPeptide
Owner:UNIV OF IOWA RES FOUND
Immune modulators in combination with radiation treatment
InactiveUS20170360932A1Good curative effectPoor prognosisPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsImmune modulatorNormal tissue
Methods for treating tumors by administering ionizing radiation and an immune modulator to a patient with cancer are disclosed. The methods provide the dual benefits of anti-tumor efficacy plus normal tissue protection when combining immune modulators with ionizing radiation to treat cancer patients. The methods described herein also allow for the classification of patients into groups for receiving optimized radiation treatment in combination with an immune modulator based on patient-specific biomarker signatures.
Owner:VARIAN MEDICAL SYSTEMS
Anti-fibroblast activation protein antibodies and methods and uses thereof
InactiveUS8999342B2Reduce the amount requiredReduce the numberSugar derivativesAntibody ingredientsAnticarcinogenImmune modulator
Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and / or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.
Owner:LUDWIG INST FOR CANCER RES
Novel pd-1 immune modulating agents
ActiveUS20180127502A1Modulate immune responsePeptide/protein ingredientsAntibody mimetics/scaffoldsAntigen bindingT cell
The present application provides anti-PD-1 antigen-binding proteins or a fragment thereof, as well as nucleic acids encoding anti-PD-1 antigen-binding proteins or CAR T cells expressing such antigen-binding protein or fragment. Also provided are methods of regulating T cells or treating patients using such constructs or cells.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT +1
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
ActiveUS20180369329A1InducesOrganic active ingredientsPeptide/protein ingredientsIMMUNE STIMULANTSImmune modulator
The present invention provides a method of treating cancer with an integrin-binding-Fc fusion protein alone or in combination with IL-2 and / or an immune stimulant (i.e., an immune checkpoint stimulator), and / or an immune checkpoint inhibitor. The invention also provides composition for use in such methods.
Owner:XYENCE THERAPEUTICS INC
Novel T cell immune modulator bioactivity detection method
ActiveCN107916276ASuitable for quality controlSuitability for detectionMicrobiological testing/measurementNucleic acid vectorCellular componentImmune modulator
The invention relates to the technical field of biological medicines, and particularly discloses a novel T cell immune modulator bioactivity detection method. Eukaryotic expression plasmids and co-expression resistance genes of sleeping beauty transposase and reporter genes driven by different response elements are expressed, eukaryotic expression plasmids of transposon inverted repetitive sequences are inserted into two ends of the reporter genes and the co-expression resistance genes and jointly transferred into host Jurkat T cells, pressurized screening and monoclonal separation are performed to obtain stable monoclonal effect cells, target cells and T cell activating modulators are added, and bioactivity of T cell immune modulator is measured by measuring activity of the reporter genes. The method can be applied to a bioactivity reporter gene detection system for cell immune modulators such as PD-1 / PD-L1 monoclonal antibodies and CTAL4-Fc fusion proteins. Any human blood-derived cell components or other components are omitted, testing results are stable, operation is simple and convenient, testing time is short, and the method is quite suitable for later drug quality control and batch release detection and can be widely applied.
Owner:BEIJING DONGFANG BIOTECH
B7S1: an immune modulator
Owner:UNIV OF WASHINGTON
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com